ECTOPIC OSSIFICATION FOLLOWING TOTAL HIP ARTHROPLASTY: IS DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS A RISK FACTOR?

BY H. FAHRER, P. KOCH, P. BALLMER, P. ENZLER AND N. GERBER

Departments of 1Rheumatology and 2Orthopaedic Surgery, University of Bern, Inselspital, CH-3010 Bern, Switzerland

SUMMARY

Total hip arthroplasty may be followed by ectopic bone formation. An increased frequency has been suspected in patients with diffuse idiopathic skeletal hyperostosis (DISH). In 204 patients we found that, of the 38 subjects with pre-existing DISH, 29% developed postoperative ossification compared with only 10% in those without DISH (p < 0.01). DISH is therefore a risk factor for postoperative ectopic bone formation. In a separate study of 1325 patients (not analysed for spinal DISH), we looked for correlations between the severity of postoperative ectopic bone and clinical measurements. Even for the more severe ossification grades (n = 112), only 10% reported serious pain and only 26% had reduced hip flexion (< 70°). Thus, periprosthetic ectopic bone is not sufficiently important to justify the routine use of preventative drugs such as bisphosphonates in patients with DISH undergoing total hip replacement.

KEY WORDS: Ectopic bone, Hip arthroplasty, Diffuse idiopathic skeletal hyperostosis.

The formation of periprosthetic ectopic calcification and ossification in the first months following total hip replacement arthroplasty is well known. (In this paper we will use only the term 'ossification'. Persistent calcification usually becomes trabecular with time.) Reports of its frequency vary. A notable degree of periartricular postoperative ossification was seen in 5% of Charnley's patients [1]. Others have reported frequencies of 8–90% [2–6].

No consensus is found in the literature about the clinical significance of this abnormality in terms of pain or reduced motion (ROM). However, symptoms seem to occur in 1–5%, especially loss of movement [7].

Predisposing factors which have been examined include operative technique, haemorrhage and infection [1, 8, 9]. DeLee et al. [3] stated that the degree of preoperative reduced ROM influenced the amount of postoperative ossification. Male sex, osteoarthritis, hyperglycaemia and obesity are other factors which have been incriminated [2, 10–12]. Several authors have suggested that DISH (formerly called Forestier's disease) might be a risk factor (Fig. 1) [2, 13–16], others have denied any influence of DISH [17].

The objective of this retrospective radiological and clinical study was to elucidate two questions. First, do patients with pre-existing spinal hyperostosis develop ectopic bone more frequently around their hip arthroplasty than controls without DISH? Second, are such bone formations associated with serious pain or restricted hip function?

PATIENTS AND METHODS

There were two groups of patients: Group I consisted of 204 consecutive patients with an original M.E. Müller straight-stem prosthesis, operated on in the years 1977/1978 (subgroup Ia, n = 91) and 1979/1980 (subgroup Ib, n = 113), respectively. They all underwent sur-

Submitted 17 August; revised version accepted 10 November 1987.

Address correspondence to Heinz Fahrer, MD.
TABLE I
CLASSIFICATION FOR ECTOPIC PERIPROSTHETIC BONE FORMATION*

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Islands of bone within the soft tissues about the hip.</td>
</tr>
<tr>
<td>II</td>
<td>Bone spurs from the pelvis or proximal end of the femur, leaving at least 1 cm between opposing surfaces.</td>
</tr>
<tr>
<td>III</td>
<td>Bone spurs from the pelvis or proximal end of the femur, reducing the space between opposing bone surfaces to less than 1 cm.</td>
</tr>
<tr>
<td>IV</td>
<td>Apparent bone ankylosis of the hip.</td>
</tr>
</tbody>
</table>

* After Brooker et al. [4].

surgery in the University Clinic for Orthopaedic Surgery in Bern. These patients were followed up after 5 years in 1983 and 1985, respectively. Of the 204 patients 117 were men with a mean age of 67±8 (range 43–84) years at follow-up, and 87 were women, mean age 70±10 (range 35–89).

Group II consisted of 1325 patients with a Müller prosthesis, operated on in different Swiss clinics for orthopaedic surgery and examined again after 1 year (mean age: men 64±9; women 66±11).

Radiological investigation
At the 5-year follow-up, all the patients of group I had an anteroposterior radiograph of the pelvis. In addition, patients in subgroup Ia (n = 91) had anteroposterior (AP) and lateral radiographs of the thoracic and/or lumbar spine. Those of subgroup Ib (n = 113) had AP and lateral radiographs of the chest and 49 had additional spinal views.

A rheumatologist (H.F.) and two orthopaedic surgeons (P.B. and P.E.) first examined all radiographs of the spine and chest of group I independently, looking for DISH. The criteria used were those of Resnick [18], and required flowing calcification and ossification along the anterolateral aspect of at least four contiguous vertebral bodies and absence of extensive 'degenerative' disc disease. Radiographs which did not completely fulfil these criteria were classified as 'probable DISH'. The individual assessments were compared and where discordant, the films were regraded by both observers together. The pelvic radiographs of group I were evaluated similarly for any ectopic bone formation about the prosthesis. Radiographs of spine and pelvis were not seen simultaneously, thus making the grading 'blind'.

The degree of ossification was defined according to the scale of Brooker (Table I) [4, 7]. This refers to ossification situated between the greater trochanter and the upper border of the acetabulum, and was adequate since changes develop laterally in 94% [3] (Fig. 2).

All group II-patients had an AP radiograph of the pelvis 1 year after operation but views of the spine were not routinely obtained.

Clinical investigation
In group II, we graded patients' hip pain as none, slight, moderate or severe 1 year postoperatively and measured their maximal hip flexion as >90°, 70–90°, 30–70° or <30°.

RESULTS
The radiological prevalence of DISH was 38/204 (19%) (Table II). In subgroup Ia the prevalence of DISH was 25%, higher than in the subgroup Ib (13%). In more than half of the patients in subgroup Ib the diagnosis of DISH had to be made from a chest radiograph. DISH was more frequent in men than in women.

Table III shows the frequency of the different degrees of postoperative ossification (0–IV). The main findings are illustrated in Fig. 3 and 74% of 38 DISH probands formed postoperative grade I–IV ossification, compared with only 58% of the 151 non-DISH probands. The difference was not significant ($\chi^2 = 2.65$, $p = 0.1$). When only the more severe grades III and IV were compared, there were 29% in the DISH-probands and 10% in non-DISH-probands ($\chi^2 = 7.72$, $p < 0.01$).

The correlations between postoperative ossification, pain and reduced ROM are shown for group II in Fig. 4. Of patients with no or
slight ossifications (classes 0–II), 4% experienced moderate or severe pain. In patients with marked ossification (classes III–IV) the frequency was 10%. Postoperative flexion of less than 70° was found in 6% of grades 0–II and in 26% of grades III–IV. Both findings were statistically significant ($\chi^2 = 9.8, p < 0.01; \chi^2 = 54.19, p < 0.001$, respectively).

### DISCUSSION

The prevalence of spinal DISH in 19% of our population agrees with previous published studies of similar ages [7, 11, 12], as does the greater prevalence of ossification in men [2, 3, 10, 11].

Severe postoperative ectopic bone formation around the hip arthroplasty was three times more frequent in those with spinal DISH. Irrespective of DISH, other authors have noted postoperative ossification in 10% of patients [3, 8].

This threefold increased frequency in DISH-probands supports the hypothesis that DISH predisposes to ectopic bone formation as part of a generalized 'ossifying diathesis'. Blasingame et al. [7] suggested a correlation between vertebral hyperostosis and ectopic bone formation based on a small series of patients. Jacqueline [16] found ossification in 57 of 67 subjects with DISH, but in only 10 of 33 controls. The severity of these ossifications and the criteria used for the diagnosis of DISH were not given. Pilet et al. [11] in a similar study, used less rigorous criteria for DISH and found 22.4% postoperative ossification in subjects with DISH and 9.6% in controls (grades III–IV), and this is in accord with our results.

Our second question concerned the clinical significance of ectopic ossification. Others have suggested a relationship with pain or impaired hip function [6–8, 10, 19, 20] and Pilet et al. [11] found a favourable postoperative ROM in 66% of males with DISH compared with 83% in those without. They concluded that DISH does not contra-indicate total hip replacement.

Our results indicate that ectopic bone formation about the hip is associated less with pain than with functional impairment. We noted moderate and severe pain in our group II of 1325 arthroplasties and this was significantly more frequent in marked ossification (10% versus 4% in controls). However, this is not a striking prevalence. Restricted flexion of less than 70° was found in 26% of 'ossifying' patients versus 6% in 'non-ossifying'.

We may conclude that approximately 30% of patients with DISH develop serious ectopic bone formation following hip replacement and...
70% will remain free. Only 25% of those with ectopic bone show important loss of ROM and only 6% develop serious pain. This means that only 7.5% of all patients with DISH suffer from restricted ROM and 1.8% from pain. This low risk does not justify the use of drugs in an attempt to prevent ossification. Bisphosphonates have proved relatively effective in this situation, but the recommended 4 months of treatment is both expensive and may cause side-effects [21-23]. Prevention should be confined to patients with a history of severe ossification of the other hip or other articulations.

ACKNOWLEDGEMENT
We wish to thank particularly Professor A. St. J. Dixon, Bath, for assistance in the preparation of the manuscript.

REFERENCES
Salazopyrin EN-tabs has a favourable benefit: risk ratio for early intervention when NSAIDs alone prove inadequate, and because it works promptly, patients improve early—often within one month.

Positive action in rheumatoid arthritis

REFLECT ON HER FUTURE BEFORE IT’S TOO LATE

Salazopyrin EN-tabs has a favourable benefit: risk ratio for early intervention when NSAIDs alone prove inadequate, and because it works promptly, patients improve early—often within one month.

Positive action in rheumatoid arthritis

Salazopyrin®
EN-tabs
enteric coated sulphasalazine

Salazopyrin EN-tabs has a favourable benefit: risk ratio for early intervention when NSAIDs alone prove inadequate, and because it works promptly, patients improve early—often within one month.
NAPROSYN
ABBREVIATED PRESCRIBING INFORMATION
NAPROSYN Tablets (naproxen 250mg per tablet)
NAPROSYN 500 Tablets (naproxen 500mg per tablet)
NAPROSYN Suspension (naproxen 25mg/ml)
NAPROSYN Suppositories (naproxen 500mg per suppository)
NAPROSYN Granules (naproxen 500mg per sachet)

Uses:
Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout and acute musculo-skeletal disorders.

Dosage:
For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis: usually 500mg to 1g daily taken in two doses at 12-hour intervals. Use lowest effective dose in the elderly. For acute gout: 750mg at once, then 250mg every eight hours until the attack has passed. For juvenile arthritis in children over 5 years: 5mg/kg body weight twice daily. For acute musculoskeletal disorders: 500mg initially, then 250mg at 6-8 hour intervals as needed with a maximum daily dose after the first day of 1250mg.

Contra-indications:
Active peptic ulceration. Hypersensitivity to naproxen or naproxen sodium formulations. Aspirin/anti-inflammatory-induced allergy.

Warnings, Precautions, etc:
Episodes of GI bleeding have been reported. Use with care in patients with a history of GI disease. Use lowest effective dose in impaired hepatic function. Use with caution in patients with impaired renal function. Monitor renal function and consider reducing dosage in patients where renal blood flow is compromised (e.g. extracellular volume depletion, cirrhosis of the liver). Use lowest effective dose in impaired renal function. Use lowest effective dose in impaired hepatic function. Use lowest effective dose in impaired renal function. Use lowest effective dose in impaired renal function.

Use with caution in patients with asthma or allergic disease. Caution is required if any of the following are administered concurrently: hydantoins, anti-coagulants or highly protein-bound sulphonamides; frusemide; propranolol or other beta-blockers; lithium; probenecid; methotrexate. NAPROSYN decreases platelet aggregation and prolongs bleeding time. Use in pregnant or breast-feeding women should be avoided if possible.

Side-effects:
GI - nausea, vomiting, pain; occasionally bleeding and ulceration. Dermatological/hypersensitivity - skin rashes, urticaria, angio-oedema; rarely anaphylactic reactions, eosinophilic pneumonitis, alopecia, erythema multiforme, Stevens Johnson syndrome, epidermal necrolysis and photosensitive dermatitis. CNS - headache, insomnia, inability to concentrate, cognitive dysfunction. Haematological - thrombocytopenia, granulocytopenia, aplastic anaemia, haemolytic anaemia. Other - tinnitus, hearing impairment, vertigo, mild peripheral oedema (patients with compromised cardiac function may be at a greater risk on NAPROSYN); rarely jaundice, fatal hepatitis, nephropathy, haematuria, visual disturbances, vasculitis and ulcerative stomatitis. NAPROSYN Suppositories (loco) - rectal discomfort, soreness, burning, itching, rectal bleeding, tenesmus, proctitis.

Basic NHS Cost:
Tablets 250mg £7.60 for 60 tablets, £30.35 for 250 tablets. Tablets 500mg £14.57 for 60 tablets original pack (OP), £24.28 for 100 tablets. Suspension £8.24 for 500ml. Suppositories £2.96 for 10 suppositories. Granules £19.47 for 60 sachets.

Product Licence No.:
PL 0286/0031 - Tablets (250mg).
PL 0286/0061 - Tablets (500mg).
PL 0286/0047 - Suspension.
PL 0286/0053 - Suppositories.
PL 0286/0098 - Granules.

Further information is available from:
SYNTEX Pharmaceuticals Limited, St. Ives Road, Maidenhead, Berkshire SL6 1RD.

NAPROSYN is a trade mark.

A gentle kind of strength in osteoarthritis.

Naprosyn 500 bd gp
naproxen
For new easy-to-open pack.